✕
Not registered yet? Please contact our project manager Dr. Sara Stöber . This area is only for members of the research consortium.
✕

PANcreatic CAncer Initial Detection via liquid biopsy

Stay informed on the project!

News
31 March 2025

Stakeholder dialogue event: Call-to-Action Document

On 15 January 2025, PCE, with the support of UEG – United European Gastroenterology, proudly hosted the first PANCAID Stakeholder Dialogue Event at the European Parliament. This important gathering brought together policymakers, clinicians, researchers, and patient advocates to discuss one crucial goal: advancing early detection of pancreatic cancer.
The event featured welcome messages from MEP Nicolás González Casares and Malta’s Minister for Health, Jo Etienne Abela, alongside project insights from Prof. Klaus Pantel and Dr Ioannis Vouldis (European Commission).
Moving patient stories were shared by Ali Stunt, Patrycja Rzadkowska, and Cristina Sandín Garcia, powerfully reminding all attendees why early detection matters. The dialogue continued with an expert roundtable discussion focusing on collaborative strategies to improve outcomes.
Finally, Prof. Núria Malats introduced the PCE Research Map, encouraging stronger research connections across Europe. This event marked a significant step forward in shaping policy, fostering collaboration, and driving innovation in pancreatic cancer detection.
The discussion does not end here. A Call-to-Action document has now been published following this landmark event — highlighting clear steps for policymakers, funding agencies, researchers, and healthcare professionals.

News
13 January 2024

PANCAID’s 3rd General Assembly Meeting

We’re looking forward to PANCAID’s 3rd General Assembly Meeting later this week in Brussels, Belgium! 🇧🇪

The meeting is a key moment for all partners to come together, review our progress, and plan the next steps in our mission to improve early detection of pancreatic cancer.

We’ll kick off with a Stakeholder Event at the European Parliament, bringing together key policymakers, patients and experts to discuss the importance of joint efforts on early detection of pancreatic cancer.

We look forward to seeing you soon!

Event
7 - 9 May 2025

PANCAID at ICMRC2025!

PANCAID is excited to be part of ISMRC 2025, the leading conference on minimal residual cancer. With a dedicated booth and several PANCAID members speaking at the event, we look forward to sharing insights on early detection of pancreatic cancer and connecting with the research community.

If you’re attending, stop by our booth No. 21 to learn more about our work! See you in Nice! 🇫🇷

View all news

About

PANCAID is an international research consortium aiming to develop a minimally invasive blood test using liquid biopsy to detect pancreatic cancer to facilitate early detection of the cancer and its precursors. With 18 members from eight countries, the project has received funding for five years to potentially revolutionize current pancreatic cancer diagnosis methods and improve patient outcomes.

Learn More

Our vision

PANCAID strives to provide a minimally invasive blood test using a comprehensive panel of liquid biopsy diagnostics (LBx) for early detection of pancreatic cancer and its precursor lesions.

Read on

Why it matters

Pancreatic cancer is a malignant neoplasm that originates in the cells of the pancreas, an organ located in the abdominal cavity behind the stomach. It is known to be one of the most aggressive and deadly types of cancer, with a high mortality rate. Pancreatic cancer is often difficult to detect in its early stages, as it tends to show minimal or no symptoms until it reaches advanced stages. This makes it challenging to diagnose and treat, and contributes to its poor prognosis.

Discover more